/LSBCF
LSBCF Stock - LakeShore Biopharma Co., Ltd
Healthcare|BiotechnologyOTC
$0.84-1.02%
$0.01 (-1.02%) • Dec 19
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.27
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.98
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.92
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LSBCF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.83 – $0.84
TARGET (TP)$0.96
STOP LOSS$0.77
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.54
52W High$3.83
52W Low$0.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $614.96M | $573.42M | $687.20M | $502.95M | $257.02M |
| Gross Profit | $507.19M | $455.73M | $533.84M | $381.49M | $197.36M |
| Gross Margin | 82.5% | 79.5% | 77.7% | 75.9% | 76.8% |
| Operating Income | $-86,291,884 | $-445,832,502 | $-139,382,351 | $-118,958,663 | $-125,847,737 |
| Net Income | $-99,982,451 | $-433,464,871 | $-145,479,105 | $-236,666,727 | $-191,826,242 |
| Net Margin | -16.3% | -75.6% | -21.2% | -47.1% | -74.6% |
| EPS | $-0.94 | $-4.05 | $-1.88 | $-0.02 | $-6.67 |
Company Overview
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LSBCFBeat Rate
0%
Last 4 quarters
Avg Surprise
-91.1%
EPS vs Estimate
Beats / Misses
0/4
Last 12 quarters
Latest EPS
$-1.20
Q2 2025
EPS Surprise History
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Q2 24
-33.3%
$-0.12vs$-0.09
Q3 24
-131.0%
$-1.34vs$-0.58
Q1 25
-100.0%
$-1.60vs$-0.80
Q2 25
-100.0%
$-1.20vs$-0.60
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 20, 2026 | — | — | — | — |
Q1 2026 | Jan 19, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | — | — | — | — |
Q3 2025 | Jul 31, 2025 | $-0.17 | — | — | — |
Q2 2025 | Apr 18, 2025 | $-0.60 | $-1.20 | -100.0% | ✗ MISS |
Q1 2025 | Jan 27, 2025 | $-0.80 | $-1.60 | -100.0% | ✗ MISS |
Q4 2024 | Dec 19, 2024 | $-5.50 | — | — | — |
Q3 2024 | Sep 24, 2024 | $-0.58 | $-1.34 | -131.0% | ✗ MISS |
Q2 2024 | Apr 19, 2024 | $-0.09 | $-0.12 | -33.3% | ✗ MISS |
Q4 2023 | Dec 30, 2023 | — | $-0.86 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-1.13 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.75 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-17.98 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.85 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.14 | — | — |
Q2 2022 | Jun 29, 2022 | — | $0.45 | — | — |
Q1 2022 | Mar 30, 2022 | — | $1.76 | — | — |
Q4 2021 | Dec 30, 2021 | — | $0.67 | — | — |
Q3 2021 | Sep 29, 2021 | — | $0.23 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-1.05 | — | — |
Latest News
Loading news...
Frequently Asked Questions about LSBCF
What is LSBCF's current stock price?
LakeShore Biopharma Co., Ltd (LSBCF) is currently trading at $0.84 per share. The stock has moved -1.02% today.
What is the analyst price target for LSBCF?
No analyst price targets are currently available for this stock.
What sector is LakeShore Biopharma Co., Ltd in?
LakeShore Biopharma Co., Ltd operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is LSBCF's market cap?
LakeShore Biopharma Co., Ltd has a market capitalization of $0.03 billion, making it a small-cap company.
Does LSBCF pay dividends?
No, LakeShore Biopharma Co., Ltd does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACOGF
Alpha Cognition Inc.
$5.72
Mkt Cap: $0.0B
DMTTF
Small Pharma Inc.
$0.11
Mkt Cap: $0.0B
EMMLF
OKYO Pharma Limited
$0.01
Mkt Cap: $0.0B
IBXNF
IBEX Technologies Inc.
$1.00
Mkt Cap: $0.0B
IGXT
IntelGenx Technologies Corp.
$0.17
Mkt Cap: $0.0B
IMMPF
ImmuPharma plc
$0.09
Mkt Cap: $0.0B
KMSTF
Kadimastem Ltd
$3.21
Mkt Cap: $0.0B
OCEL
Organicell Regenerative Medicine, Inc.
$2.74
Mkt Cap: $0.0B
PMXSF
Pharmaxis Ltd
$0.03
Mkt Cap: $0.0B
RLFTD
Relief Therapeutics Holding AG
$4.08
Mkt Cap: $0.0B
Explore stocks similar to LSBCF for comparison